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Abstract
Rationale: Smoking cessation counseling in conjunction with low-dose computed tomography 
(LDCT) lung cancer screening is recommended in multiple clinical practice guidelines. The best 
approach for integrating effective smoking cessation interventions within this setting is unknown.
Objectives: To summarize evidence, identify research gaps, prioritize topics for future research, 
and propose standardized tools for use in conducting research on smoking cessation interventions 
within the LDCT lung cancer screening setting.
Methods: The American Thoracic Society convened a multistakeholder committee with expertise 
in tobacco dependence treatment and/or LDCT screening. During an in-person meeting, evidence 
was reviewed, research gaps were identified, and key questions were generated for each of three 
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research domains: (1) target population to study; (2) adaptation, development, and testing of 
interventions; and (3) implementation of interventions with demonstrated efficacy. We also 
identified standardized measures for use in conducting this research. A larger stakeholder panel 
then ranked research questions by perceived importance in an online survey. Final prioritization 
was generated hierarchically on the basis of average rank assigned.
Results: There was little consensus on which questions within the population domain were of 
highest priority. Within the intervention domain, research to evaluate the effectiveness in the lung 
cancer screening setting of evidence-based smoking cessation interventions shown to be effective 
in other contexts was ranked highest. In the implementation domain, stakeholders prioritized 
understanding strategies to identify and overcome barriers to integrating smoking cessation in lung 
cancer screening settings.
Conclusions: This statement offers an agenda to stimulate research surrounding the integration 
and implementation of smoking cessation interventions with LDCT lung cancer screening.
Keywords
research priorities; lung cancer screening; smoking cessation; tobacco dependence treatment; 
LDCT screening
Overview
Smoking cessation counseling and treatment are critical corollaries to low-dose computed 
tomography (LDCT) screening, offering an opportunity to reduce smoking-related mortality. 
Although the Centers for Medicare and Medicaid Services (CMS) requires that smoking 
cessation interventions be delivered in conjunction with lung cancer screening for Medicare 
reimbursement of LDCT screening, neither the most effective interventions nor the best 
approach for implementing those interventions with demonstrated efficacy in this setting is 
known. This research policy statement identifies consensus prioritization of diverse 
stakeholders regarding three topics for research on smoking cessation interventions in the 
context of LDCT screening: (1) target population to study; (2) adaptation, development, and 
testing of potential interventions; and (3) implementation of interventions with demonstrated 
efficacy. In each of these three domains, we summarize the existing evidence; identify 
research gaps; and, on the basis of a formal process of consensus development, prioritize 
research questions. The fourth section presents our committee’s recommendations for 
standardized tools and measures to use in conducting this research. This statement offers a 
research agenda to inform investigators as well as governmental and nongovernmental 
funding agencies to generate high-priority, high-quality research surrounding integration of 
tobacco dependence treatment with LDCT screening.
Key Conclusions and Recommendations
Population domain.
• Although there was little consensus on which questions within the population 
domain were of the highest priority, research in this area should consider 
addressing how LDCT screening results (positive or negative test results) affect 
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motivation to quit and the resultant impact on effectiveness of cessation, because 
it was ranked highest by stakeholder representatives.
Intervention domain.
• There is little data on the effectiveness of smoking cessation interventions in the 
LDCT screening setting, leaving significant knowledge gaps regarding the 
optimal method of smoking cessation counseling, timing of delivery, and 
pharmacotherapy approaches in this context.
• Research to evaluate the effectiveness of established, evidence-based 
interventions for smoking cessation in lung cancer screening settings ranked 
highest among stakeholder representatives.
Implementation domain.
• There is scant data on the implementation of smoking cessation interventions 
into lung cancer screening programs.
• A national research agenda should include strategies for implementing tobacco 
dependence treatment within the lung cancer screening setting.
• Stakeholders prioritized determining the system barriers to integrating smoking 
cessation in lung cancer screening settings, as well as researching effective 
strategies to overcome these barriers.
Standardized tools and measures.
• There was strong consensus among committee members that using standardized 
tools, measures, and outcomes in this research would increase the quality of the 
science and the ability to interpret and pool results of different studies.
• Applicable standardized measures and tools are outlined in this statement to 
provide scientists the tools with which to conduct high-quality research in this 
setting.
Introduction
Lung cancer is the leading cause of cancer death in the United States (1, 2). Over 90% of 
lung cancer deaths would be avoided if Americans never initiated cigarette smoking. 
Quitting smoking is the most effective intervention to reduce lung cancer mortality (3, 4); 
yet, approximately 36.5 million Americans continue to smoke cigarettes (2, 5). Current 
smokers between the ages of 55 and 64 years would gain 4 years of life expectancy from 
avoided lung cancer and other tobacco-related deaths if they quit smoking (6). Among 
current smokers, the number needed to intervene is as low as 77 because providing cessation 
interventions to 11 individuals leads to at least 1 additional successful quitter (7), and 
depending on age and sex, 1 early death from all tobacco-related causes can be avoided by 
helping as few as 7 individuals quit smoking, even among middle-aged and older adults (8). 
Despite the fact that nearly 70% of current smokers attempt to quit each year, only 1 to 6% 
of smokers are successful in quitting (9, 10).
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The other intervention proven to reduce lung cancer mortality is annual LDCT screening of 
middle-aged and older smokers with a substantial history of tobacco use, which is associated 
with a gain of 0.04 years of life expectancy from avoided lung cancer deaths (11, 12). The 
number needed to screen is 320 to prevent 1 early lung cancer death (11, 12). In the NLST 
(National Lung Screening Trial), individuals in the LDCT screening arm who successfully 
quit smoking had the lowest rate of lung cancer deaths (13). Thus, providing smoking 
cessation treatment in conjunction with LDCT screening offers an opportunity to combine 
two interventions known to reduce smoking-related morbidity and mortality.
Recognizing the importance of helping adults quit smoking, the CMS requires that smoking 
cessation interventions be offered to receive Medicare reimbursement of LDCT screening. 
Similarly, multiple professional organizations and the U.S. Preventive Services Task Force 
recommend that smoking cessation interventions be delivered in conjunction with LDCT 
screening (14). Yet, neither the most effective interventions nor the best approach for 
implementing those interventions with demonstrated efficacy in this setting is known.
The National Institutes of Health (NIH); the National Academies of Science, Engineering, 
and Medicine; the Association for the Treatment of Tobacco Use and Dependence; and the 
Society for Research on Nicotine and Tobacco have all highlighted the need for research on 
optimal strategies to integrate smoking cessation interventions within LDCT screening 
programs (15–17). In this research statement, we discuss the methodology and development 
of a stakeholder-endorsed research priority agenda relating to tobacco dependence treatment 
in LDCT screening programs.
Methods
The committee chair (H.K.) and cochair (R.S.W.) convened a team with expertise in LDCT 
screening and/or tobacco dependence treatment (Table 1). The team included multiple 
stakeholders representing the perspectives of scientists conducting translational, clinical, 
cost-effectiveness, implementation science, and health services research; governmental and 
nongovernmental funding agencies; professional societies; clinicians (physicians, nurses, 
and health educators specializing in pulmonary medicine, thoracic surgery, and/or tobacco 
dependence treatment); and patients. To understand diverse contexts and strategies for 
implementing smoking cessation treatment within LDCT screening programs, we selected 
individuals representing various clinical settings, including academic centers, community 
hospitals, integrated health systems, and the Veterans Health Administration. Potential 
conflicts of interest were disclosed and managed in accordance with the policies and 
procedures of the American Thoracic Society (ATS).
Our committee met in person at the May 2016 ATS International Conference. Designated 
moderators led group discussions on four topics: the effect of screening on smoking 
cessation, interventions for smoking cessation in the LDCT screening setting (not including 
interventions at the policy level), implementation of smoking cessation interventions in the 
LDCT screening setting, and standardized tools and measures to conduct research on 
smoking cessation interventions in the setting of LDCT screening. For each of these topics, 
the moderator summarized the existing evidence (based on primary literature and recent 
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systematic reviews) and identified critical gaps. Through discussion, the committee 
compiled several draft research questions in three areas: (1) target population to study; (2) 
adaptation, development, and testing of potential interventions; and (3) implementation of 
interventions with demonstrated efficacy. For the fourth topic, we discussed existing tools 
and measures to conduct high-quality research on smoking cessation and compiled lists of 
resources for investigators working in this area.
Following the in-person meeting, the chairs further refined the draft research questions to 
eliminate redundancy, with assistance from committee members. We then came to consensus 
through group discussion on 7 questions in each of the three topics (21 questions total) to be 
posed to a larger group of stakeholder representatives (Table 1) for prioritization through a 
subsequent online survey. We identified stakeholders with expertise in tobacco dependence 
treatment, inviting all members of the ATS Tobacco Action Committee as of August 1, 2016. 
We also identified stakeholders with expertise in LDCT screening by recruiting from among 
experts who participated in the July 2016 National Academies of Science, Engineering, and 
Medicine Workshop on Implementation of Lung Cancer Screening. Finally, stakeholders 
with expertise in both tobacco dependence treatment and LDCT screening were identified by 
chairs and committee members and invited to participate in the online survey. In total, 77 
stakeholders, who included representatives from payers, government and nongovernment 
agencies, patient advocacy groups, funding agencies, academic hospitals, government 
hospitals, integrated health systems, and physician and nonphysician professional 
organizations, were invited to participate in the online survey. Including our committee 
members, a total of 43 participants (56%) participated in the online survey (Table 1). Each 
stakeholder was asked to rank topics from 1 (most important) to 7 (least important) in each 
of the three topic areas, with no ties between questions within a given topic area (i.e., each 
question had to be assigned a unique rank). The final prioritization of questions was 
generated hierarchically on the basis of average rank assigned (lowest to highest).
The chairs drafted the initial version of the manuscript of this document with assistance 
from committee members. The manuscript was circulated to the full committee and 
iteratively revised. The final document was approved by the ATS Board of Directors.
Results
The results are organized into four sections designed to help scientists and funding agencies 
conduct and assess research related to integration of smoking cessation interventions with 
LDCT screening. The first three sections correspond to the three topics in which questions 
were prioritized: (1) target population to study; (2) adaptation, development, and testing of 
potential interventions; and (3) implementation of interventions with demonstrated efficacy. 
The fourth section presents our committee’s recommendations for standardized tools and 
measures to conduct this research.
Target Population to Study (Who?)
Summary of evidence and research gaps.—The existing literature provides a 
rationale for studying smoking cessation interventions in specific populations. Within the 
NLST, current smokers, those with less than a high school education, and black individuals 
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had higher rates of lung cancer death (13). Certain groups, including socioeconomically 
disadvantaged groups, individuals with comorbid substance use or psychiatric disorders, and 
certain racial and ethnic minorities, are less likely to be offered, to use, and to successfully 
complete evidence-based tobacco dependence treatment (10, 18–20). It has been suggested 
that LDCT screening may provide a “teachable moment” for these underserved smokers and 
an opportunity to offer smoking cessation interventions at a time when these individuals are 
more cognizant of the potential harms of smoking and thus more likely to be receptive to 
interventions (21, 22).
Recommendations and clinical practice guidelines to date have not consistently endorsed the 
allocation of intervention resources to subgroups of smokers on the basis of patient factors 
such as motivation to quit or self-efficacy. In the Danish Lung Cancer Screening Trial, 
higher motivation to quit at baseline predicted smoking status both 1 year after screening 
and at the end of a 5-year screening program (23, 24). Several other factors, such as older 
age, poorer lung function, greater perceived advantages of quitting, and higher self-efficacy, 
were associated with abstinence at 1 year (23, 25). Historically, providers and quitlines have 
been encouraged to identify a patient’s willingness to quit and provide cessation treatment 
only to those patients who have a clear intent to quit (26). However, recent trials have 
suggested that providing cessation treatment to all smokers, regardless of their current 
willingness to quit, may help more smokers quit (26).
Other populations that may be of particular interest for study are defined by the results of 
LDCT screening. Two recent systematic reviews showed that undergoing LDCT screening in 
itself is not sufficient to achieve long-term smoking abstinence (27, 28). On one hand, 
however, there is some evidence that positive LDCT screening results (e.g., detection of 
nodules) are associated with increases in quit rates and in reducing relapse among recent 
quitters (23, 24, 27, 29). On the other hand, screening may have paradoxical effects because 
others with a screen-detected nodule may be too scared or anxious to tackle quitting 
smoking (30), and patients with a normal LDCT screening result may feel little urgency to 
quit (31). Of note, among all persons screened, 80 to 86% have a normal or low-risk result 
(American College of Radiology Lung CT Screening Reporting and Data System [“Lung-
RADS”] category 1 or 2) (32, 33).
Stakeholder prioritization of research questions.—Of 43 stakeholders, 37 ranked 
questions relating to “population to study.” This first domain includes questions that 
investigate the subgroups of patients (moderators) with greatest intervention efficacy. Voting 
results indicated that four of the seven questions were ranked as most or second most 
important by nearly equal numbers of experts. Mean rank scores across all seven questions 
showed little variability in mean scores (range, 3.43–4.73; possible range, 1 = most 
important to 7 = least important) (Table 2).
Adaptation, Development, and Testing of Potential Interventions (What and When?)
Summary of evidence and research gaps.—There is little data on the effectiveness of 
smoking cessation interventions in the LDCT screening setting (25, 34–39), leaving 
significant knowledge gaps regarding the optimal method of smoking cessation counseling, 
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timing of delivery, and pharmacotherapy approaches in this context. Overall, in screened 
patients, more intensive interventions appeared to be associated with greater improvement in 
6-month smoking abstinence and readiness to quit. In one retrospective case–control study 
analyzing self-reported physician interventions and quit rates by NLST participants, using 
the U.S. Public Health Service–recommended “5 A’s” approach, the “assist” (connecting 
smokers with evidence-based treatment) and “arrange follow-up” steps increased the odds of 
quitting by 40 and 46%, respectively (25). To our knowledge, no studies to date have 
evaluated the utility and safety of novel approaches such as electronic nicotine delivery 
systems as a bridge to quitting, financial incentives, mobile technology–based interventions, 
or patient navigation for smoking cessation in the context of LDCT screening.
Prioritization of research questions.—Of the 43 stakeholders, 36 ranked seven 
questions relating to “intervention to study.” Final voting results indicated that researching 
“the effectiveness of established, evidence-based interventions for smoking cessation in lung 
cancer screening settings” was a strong priority based on stakeholder rankings in this area 
(mean score, 2.86; possible range, 1 = most important to 7 = least important) (Table 3). By 
contrast, the lowest-ranked question, “What is the optimal intensity of smoking cessation 
interventions in lung cancer screening setting? What is the comparative effectiveness of 
interventions that vary in intensity?” received a ranking of 5.03.
Implementation of Interventions with Demonstrated Efficacy (How?)
Summary of evidence and research gaps.—There is scant data on the 
implementation of smoking cessation interventions into LDCT screening programs; this has 
been identified as an area for further research (40–42). LDCT screening programs vary in 
terms of resources and referral pathways for providing smoking cessation interventions. A 
recent national survey suggested that most LDCT screening programs do not currently offer 
guideline-based tobacco dependence treatment (42). For example, NLST participants 
reported that their primary care providers only partially followed the U.S. Public Health 
Service–recommended “5 A’s” recommendations: Whereas the majority “asked,” “advised,” 
and “assessed,” only half “assisted” smokers in connecting to treatment, and only 10% 
“arranged follow-up” (25). Little research has been done to explore the barriers to, 
facilitators of, and most effective implementation strategies for delivering smoking cessation 
interventions in the LDCT screening setting.
Prioritization of research questions.—Of 43 stakeholders, 35 ranked seven questions 
relating to implementation. Final voting results indicate that “What are the system barriers to 
integrating smoking cessation in lung cancer screening settings, and what are the effective 
strategies to overcome these barriers?” and “What are effective strategies for implementing, 
disseminating, and scaling up cessation interventions in the real world?” received similar 
priority rankings (3.06 and 3.17, respectively), with little separation in priority scores 
between the two (Table 4). By contrast, the lowest-ranked topic had a priority score of 5.49.
Standardized Tools and Measures to Conduct High-Quality Research
There was strong consensus among committee members that using standardized tools, 
measures, and outcomes in this research would increase the quality of the science and the 
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ability to interpret and pool results of different studies. Other professional organizations 
have issued recommendations about measures of tobacco abstinence and biochemical 
confirmation in conducting trials of smoking cessation interventions, which our committee 
agreed would be applicable in the context of LDCT screening as well.
Recommended measures and other considerations for smoking cessation 
trials.—Standards for measurement are provided in three existing documents issued by 
other groups: (1) the Society for Research on Nicotine and Tobacco Task Force (43), (2) 
West and colleagues (the Russell Standard) (44), and the (3) Smoking Cessation at Lung 
Examination (SCALE) Collaboration (45). The recommendations of the Society for 
Research on Nicotine and Tobacco and Russell Standard documents on abstinence measures 
are summarized in Figure 1. The SCALE Collaboration is a National Cancer Institute (NCI)-
sponsored initiative to develop and test smoking cessation interventions in the setting of 
LDCT screening; recommended consensus measures in the domains of demographics and 
psychological characteristics, medical characteristics and outcomes, tobacco use behavior, 
implementation, and organizational characteristics from the SCALE Collaboration are 
summarized in Table E1 in the online supplement. To facilitate research collaboration in this 
setting, the SCALE panel of 19 funded investigators and NCI scientists formed work groups 
within content areas. Groups convened in person at facilitated meetings and/or by 
teleconference over a 2-month period (October–December 2016) to reach consensus on the 
selection of the most important measures for smoking cessation trials in the LDCT screening 
context. The following measures are publicly available:
• Demographics (date of birth, sex, race, ethnicity, education, and income)
• Psychological characteristics (depressive symptoms, measured by the K-6 [46])
• Perceived risk of developing lung cancer (“How likely do you think it is that you 
will develop lung cancer in your lifetime?” and “Compared with other smokers, 
what do you think your chance of getting lung cancer is in your lifetime?”)
• Lung cancer worry (“How worried are you about getting lung cancer in your 
lifetime?”)
• Family history of lung cancer
• Family history of any cancer
• The Fagerström Test for Nicotine Dependence (47)
• The cessation Contemplation Ladder (48)
• Confidence/self-efficacy to quit (49)
• History of other tobacco use (50)
• Smoking status (“Have you smoked a cigarette, even a puff, in the past 7 days?” 
and “Have you smoked a cigarette, even a puff, in the past 30 days?”)
Consensus measures also include implementation measures, medical outcomes, and 
organizational characteristics (Table E1). The full measure collection is publicly available in 
the NCI Grid-Enabled Measures Database (45). The NCI Grid-Enabled Measures Database 
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is an interactive website that contains behavioral and social science measures organized by 
theoretical constructs. The NIH-funded Patient-Reported Outcomes Measurement 
Information System comprises a set of person-centered measures that are used to evaluate 
and monitor physical, mental, and social health (www.healthmeasures.net). Both are useful 
resources for developing instruments for smoking cessation trials.
These three groups (Society for Research on Nicotine and Tobacco Task Force, West and 
colleagues [44], and the SCALE Collaboration) agree that abstinence from tobacco use is 
the most important outcome to measure when evaluating the clinical effectiveness of a 
smoking cessation intervention. Outcomes measured at a longer duration from the 
intervention (e.g., 6-mo or 1-yr quit rates) are considered more robust than outcomes 
measured at a shorter interval (e.g., 1-mo quit rates). When feasible, biochemical 
confirmation should be obtained. Biochemical markers include cotinine, carbon monoxide, 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), or anabasine and anatabine (Table 
5).
Use of standardized measures of exposures is also important for interpretation of research 
results in smoking cessation trials. The National Human Genome Research Institute, with 
cofunding by the National Institute on Drug Abuse, has developed a publicly available Web-
based resource, the PhenX Toolkit (www.phenxtoolkit.org) (51), which compiles high-
quality standard measures of phenotypes and environmental exposures for use in biomedical 
research. The Food and Drug Administration’s Center for Tobacco Products and the NIH 
Tobacco Regulatory Science Program are expanding the tobacco-related measures in the 
PhenX Toolkit. This toolkit currently includes measures relevant to tobacco research, such as 
(1) demographic measures; (2) descriptive, behavioral, or biological measures that 
characterize tobacco product use; (3) measures that characterize intrapersonal factors that 
influence product use; and (4) protocols and assays for tobacco smoke products. Examples 
of the measures available via this Web-based resource that are relevant to this policy 
statement are shown in Table E2.
Study design is an important consideration when generating high-quality research. Although 
the randomized controlled trial are the only study design that can be used to measure 
efficacy directly, observational designs may be particularly useful in evaluating smoking 
cessation interventions. For example, randomized controlled trial participants must have 
enough desire to enroll in the trial, potentially limiting generalizability to the many patients 
who are not currently interested in quitting. The ATS developed a statement on comparative 
effectiveness research that may help researchers and funders decide when nonrandomized 
designs may be most helpful in smoking cessation studies (52).
Discussion
Under the auspices of the ATS, our committee employed a formal process of consensus 
development to produce a national research agenda for smoking cessation interventions 
within LDCT screening programs in collaboration with a diverse set of stakeholders. A 
complete list of stakeholder-endorsed research priorities is available in Tables 2–4. 
Stakeholder preferences were strongest for the following questions within each domain:
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• Population: How do LDCT screening results (positive or negative test results) 
affect motivation to quit, and what is the resultant impact on the effectiveness of 
cessation?
• Intervention: What is the effectiveness of established, evidence-based 
interventions for smoking cessation in lung cancer screening settings?
• Implementation: What are the system barriers to integrating smoking cessation in 
lung cancer screening settings, and what are the effective strategies to overcome 
these barriers?
In comments and discussions with voting members, researching how LDCT screening 
results affect motivation to quit, as well as the resultant impact on effectiveness of cessation, 
was prioritized within the population domain because it is likely to influence how screening 
providers communicate with patients about their results and provide messages about 
smoking cessation. Whereas the CMS highlights the importance of integrating smoking 
cessation counseling in the initial shared decision-making conversation about screening, the 
voting members highlighted that post-screening messaging and interventions related to 
smoking cessation may also be a critical priority.
Within the intervention domain, the topic of developing an evidence base for understanding 
how established interventions that have been demonstrated to be effective in other settings 
perform in the LDCT screening context was prioritized in part because screening providers 
are eager to ensure that the cessation interventions they provide are effective in this setting. 
Many voting members emphasized that providing the most effective care possible is a 
priority and should be guided as much as possible by research evidence. Within the 
implementation domain, stakeholders identified that a clear challenge to increasing smoking 
cessation within the LDCT screening setting is ensuring that evidence-based interventions 
are fully implemented. As highlighted by Park and colleagues, less than 10% of providers 
fully provided cessation services, in part because of limitations of clinician time and 
resources (25). To maximally reduce lung cancer mortality, it is critical to overcome barriers 
to referring high-risk smokers for both LDCT screening and tobacco dependence treatment 
and to support implementation of full-service LDCT screening programs capable of 
providing evidence-based tobacco dependence treatment.
Stakeholders were more consistent across rankings for the domains of intervention and 
implementation, in each case prioritizing one or two questions as clear priorities, whereas 
rankings were more widely dispersed across the questions within the population domain. Of 
note, multiple stakeholders contacted the chairs to comment on how difficult it was to rank 
these questions because they considered all of them important, and not all stakeholders 
ranked questions in all domains, which may similarly indicate difficulty in assigning relative 
priority to the questions. Nonetheless, each topic represents the consensus prioritization of 
diverse stakeholders and provides an agenda for research on smoking cessation interventions 
in the context of LDCT screening.
This research is urgently needed, as recognized by multiple organizations, including the NIH 
and the National Academies of Science, Engineering, and Medicine (17, 53). The NCI 
recently awarded six R01 grants to develop and test smoking cessation interventions for 
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current smokers undergoing LDCT lung cancer screening (45, 53). The standardized 
measures and approaches outlined in this document provide scientists the tools with which 
to conduct high-quality studies using a variety of methods (explanatory trials, pragmatic 
trials, mixed methods, comparative effectiveness) to answer these questions and to assess 
mechanisms through which intervention effects may occur (mediators such as psychological 
characteristics, perceived lung cancer risk, self-efficacy/confidence to quit). This statement 
provides a road map for scientists and government and nongovernment funding agencies to 
use in generating high-priority, high-quality research to answer pressing questions 
surrounding integration of tobacco dependence treatment within LDCT screening 
screenings. We hope this statement will stimulate the research needed to provide answers to 
clinicians and administrators seeking to deliver effective smoking cessation interventions to 
smokers undergoing LDCT screening, thereby improving care and ultimately reducing lung 
cancer mortality.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Summary of recommendations for trials of smoking cessation interventions.
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Table 1.
Stakeholder Representatives and Affiliations
Expertise
 Representative Affiliation Specialty Smoking Cessation LDCT Screening
Individuals with expertise identified by chairs
 Chunxue Bai Zhongshan Hospital, Fudan University, 
China
Pulmonology x
 Belinda Borrelli Boston University Health psychology x
 Frank C. Detterbeck* Yale University Thoracic surgery x
 Tom Glynn Stanford University Tobacco control x
 Michael K. Gould* Kaiser Permanente Pulmonology x
 Joelle T. Fathi* Swedish Cancer Institute Nursing x x
 Denise G. Jolicoeur* University of Massachusetts Medical School Health educator x
 Hasmeena Kathuria* Boston University Pulmonology x x
 Peter J. Mazzone* Cleveland Clinic Pulmonology x
 Georgia L. Narsavage University of South Carolina Nursing x
 Gerard A. Silvestri* Medical University of South Carolina Pulmonology x x
 Christopher G. Slatore* VA Portland Health Care System Pulmonology x x
 M. Patricia Rivera University of North Carolina at Chapel Hill Pulmonology x
 Martin Tammemagi Brock University, Canada Epidemiology x
 Anil Vachani* University of Pennsylvania Pulmonology x x
 Carlijn van der Aalst Erasmus MC, the Netherlands Pulmonology x x
 Juan Wisnivesky Icahn School of Medicine at Mount Sinai Pulmonology x x
 Renda Soylemez Wiener* Bedford VA Medical Center/Boston 
University
Pulmonology x
 Steven B. Zeliadt* VA Puget Sound Health Care System Health economist x x
 Funding agencies
  Stephanie R. Land* National Cancer Institute Tobacco control
  Greta M. Massetti* CDC
 Patients and patient advocacy groups
  Kathleen Fennig* Patient representative
  Robert A. Smith* American Cancer Society
Additional stakeholders identified through other sources
 ATS Tobacco Action Committee
  Michelle Eakin Johns Hopkins University
  Harold Farber Texas Children’s Hospital
  Patricia Folan Northwell Health
  Frank Leone University of Pennsylvania
  Farzad Moazed University of California, San Francisco
  Smita Pakhale Ottawa Hospital Research Institute
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Expertise
 Representative Affiliation Specialty Smoking Cessation LDCT Screening
 National Academy of Sciences Implementation of Lung Cancer Screening Workshop
  Caroline Chiles Wake Forest Baptist Health Center
  Angela Criswell Lung Cancer Alliance
  Richard Hoffman University of Iowa
  Ella Kazerooni University of Michigan
  Jane Kim Durham VA Medical Center/Duke University
  Kelly Latimer U.S. Naval Hospital Sigonella, Italy
  Michael LeFevre University of Missouri
  Ide Mills Patient advocate
  Elyse Park Massachusetts General Hospital
  Joshua Roth Fred Hutchinson Cancer Research Center
  Jamie L. Studts University of Kentucky College of Medicine
  Helene Vitella Bristol-Myers Squibb Co.
 Awardees of NCI Request for Applications on Smoking Cessation Interventions in LDCT Screening
  Kristie Foley Wake Forest School of Medicine
  David Midthun Mayo Clinic
  Kathryn Taylor Georgetown University
  Benjamin Toll Medical University of South Carolina
Definition of abbreviations: ATS = American Thoracic Society; LDCT = low-dose computed tomography; NCI = National Cancer Institute; VA = 
Department of Veterans Affairs.
*
Indicates the individual was a member of the American Thoracic Society committee tasked with generating this statement.
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Table 2.
Stakeholder Prioritization of Questions: Population to Study (n = 37)
 Final Rank Question Mean Score
Percentage 
Who Ranked 1 
or 2
1 How do LDCT screening results (positive or negative test results) affect motivation to quit, 
and what is the resultant impact on effectiveness of cessation?
3.43 37.8%
2 How do patients’ beliefs, attitudes, and perceived or real barriers to quitting impact the 
effectiveness of cessation interventions in the context of lung cancer screening?
3.49 32.4%
3 How does motivation to quit impact the effectiveness of cessation interventions in lung 
cancer screening? What approaches are most effective among smokers with low 
motivation to quit?
3.68 32.4%
4 Who benefits the most from evidence-based interventions for smoking cessation in lung 
cancer screening? Evidence-based cessation interventions include counseling, nicotine 
replacement, and other pharmacotherapy, alone or in combination.
4.11 32.4%
5 What are the characteristics of populations for whom evidence-based cessation 
interventions are not effective? Examples might include smokers with comorbid mental 
health, physical, or substance use disorders; individuals of low socioeconomic status; or 
members of racial or ethnic minority groups.
4.14 21.6%
6 For patients who undergo a shared decision-making visit about lung cancer screening and 
decide not to get screened, what is the effectiveness of smoking cessation interventions, 
and how does it vary from patients who do undergo lung cancer screening?
4.43 24.3%
7 For patients who recently quit smoking, how does lung cancer screening impact smoking 
relapse and patients’ motivation to stay quit?
4.73 18.9%
Definition of abbreviation: LDCT = low-dose computed tomography.
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Table 3.
Stakeholder Prioritization of Questions: Intervention to Study (n = 36)
 Final Rank Question Mean Score
Percentage 
Who Ranked 
1 or 2
1 What is the effectiveness of established, evidence-based interventions for smoking 
cessation in lung cancer screening settings? Evidence-based cessation interventions include 
counseling, nicotine replacement, and other pharmacotherapy, alone or in combination.
2.86 52.8%
2 What are the most effective strategies for counseling patients to quit smoking in the lung 
cancer screening setting? (In other words, is it necessary to tailor messaging to this setting, 
and if so, what are the essential elements to be included in messaging in the lung cancer 
screening setting?)
3.25 41.7%
3 What is the most effective platform to promote use of evidence-based cessation 
interventions in lung cancer screening settings? Examples of platforms include patient 
navigators, health maintenance alerts, and texting.
3.89 33.3%
4 How effective are novel/innovative smoking cessation interventions in lung cancer 
screening settings compared with established, evidence-based interventions for smoking 
cessation? Examples of novel innovative interventions include mobile health applications, 
e-cigarettes, and financial incentives.
4.11 27.8%
5 Among patients who do not benefit from generic evidence-based cessation interventions, is 
an intervention tailored to their specific needs more effective?
4.22 11.1%
6 How does the effectiveness of smoking cessation interventions in lung cancer screening 
vary depending on when they are delivered (e.g., before vs. after screening; cessation 
offered at one time point vs. at multiple time points longitudinally)?
4.64 19.4%
7 What is the optimal intensity of smoking cessation interventions in lung cancer screening? 
What is the comparative effectiveness of interventions that vary in intensity?
5.03 13.9%
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Table 4.
Stakeholder Prioritization of Questions: Implementation (n = 35)
 Final Rank Question Mean Score
Percentage 
Who Ranked 
1 or 2
1 What are the system barriers to integrating smoking cessation in lung cancer screening 
settings, and what are the effective strategies to overcome these barriers? For example, what 
are the strategies to address issues with time and resource constraints, reimbursement 
issues, and opportunities to use technology/EMRs?
3.06 45.7%
2 What are effective strategies for implementing, disseminating, and scaling up cessation 
interventions in the real world? How do feasibility, reach, cost, patient/provider 
engagement, fidelity, and ease of delivery impact dissemination with quality?
3.17 45.7%
3 Which platforms to promote smoking cessation can be most easily integrated and have the 
lowest barriers to adoption in the lung cancer screening setting? Examples include texting, 
phone counseling, quit lines, and in-person visits
3.26 34.3%
4 What are the scalable, reproducible models for training that maximize provider 
effectiveness for smoking cessation in lung cancer screening?
3.91 25.7%
5 Which professionals are most effective at delivering smoking cessation interventions in 
lung cancer screening? Examples include primary care providers, peer navigators, nurses, 
and a team approach.
4.17 22.9%
6 How do provider characteristics influence the effectiveness of smoking cessation 
interventions in the context of lung cancer screening? Examples of provider characteristics 
include perceptions of the evidence for cessation interventions; competing priorities; 
communication skills, bias, and attitudes regarding smoking; and knowledge about and 
training in smoking cessation interventions.
4.94 14.3%
7 How do site characteristics impact the effectiveness of cessation interventions in lung 
cancer screening? Examples of site characteristics include comprehensive screening 
programs versus ad hoc screening, sites that permit self-referral compared with those that 
accept only provider-referred patients, reimbursement for cessation, and demographics and 
case mix of patients served.
5.49 11.4%
Definition of abbreviation: EMR = electronic medical record.
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Table 5.
Comparison of Biomarkers for Tobacco Use
Cotinine Carbon Monoxide NNAL Anabasine and Anatabine
What is it? Major 
metabolite of 
nicotine
Combustible 
byproduct from 
cigarette smoking
Tobacco-specific nitrosamine metabolite Two nicotine-related 
alkaloids present in 
tobacco
Measured in what samples? Plasma, 
saliva, and 
urine
Expired air Urine Urine
Relative sensitivity/specificity More 
sensitive than 
CO, but less 
specific as it 
cannot 
distinguish 
NRT from 
tobacco use
Reasonably 
sensitive for recent 
or heavy cigarette 
use; does not 
detect smokeless 
tobacco or NRT
Highly tobacco specific; can distinguish 
NRT from tobacco; detects smokeless 
tobacco
Specific for tobacco use 
(not present in NRT); able 
to detect smokeless 
tobacco
Suggested cutoff for positive 
result*
30 ng/ml for 
urine; 3–5 
ng/ml for 
serum and 
saliva
5–6 ppm 47.3 pg/ml 2 ng/ml
Half-life 16–18 h; 
biochemically 
verifiable 
window 7 d
2–8 h; 
biochemically 
verifiable window 
1 d
10–18 d; detected in urine for 6–12 wk 10–16 h
Definition of abbreviations: CO = carbon monoxide; NNAL = 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; NRT = nicotine replacement 
therapy; ppm = parts per million.
Data from References 43, 54, and 55.
*Cutoff points may vary depending on individual’s smoking behavior, product, genetic background, and magnitude of secondhand smoke.
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